#South Korea #Seoul #antibiotic resistance #Seegene #Nature Awards

Seegene and Springer Nature Launch 2025-2026 Nature Awards MDx Impact Grants

Seegene Inc., a global leader in molecular diagnostics, has officially announced the opening of applications for the Nature Awards MDx Impact Grants for the 2025–2026 cycle. This initiative, in collaboration with Springer Nature, aims to tackle the pressing public health challenge of antibiotic resistance in urinary tract infections (UTI-DR).

Program Overview

The Nature Awards MDx Impact Grants program is now entering its third iteration since its inception in 2023, inviting innovative researchers from around the globe to submit proposals for product development and clinical research projects. Applicants are encouraged to identify unmet clinical needs related to antibiotic resistance, proposing up to 18 resistance genes linked to urinary tract infections for testing objectives.

Funding for the selected projects can reach up to $600,000, along with access to Seegene’s syndromic PCR testing, consumables, instruments, and software to support the creation of groundbreaking diagnostic solutions. The final awardees will be announced in August 2026, creating an exciting platform for advancements in healthcare diagnostics.

Commitment to Scientific Advancement

Richard Hughes, Vice President of Publications at Springer Nature, highlighted the company's dedication to connecting scientists and amplifying innovative research. He emphasized, “Through this program, we aim to assist researchers in developing diagnostic solutions that can significantly impact healthcare worldwide.” This cooperation stands testament to both organizations’ commitment to medical advancement and the dissemination of scientific knowledge.

Dr. Jik Young Park, Vice President and Chief R&D Officer of Seegene, stated, “Our role is to provide the necessary tools and technologies to scientists and researchers capable of transforming innovative ideas into real-world solutions. In close partnership with Springer Nature, we aim to drive global research efforts by supporting scientists with funds and access to our syndromic PCR technologies.” The overarching goal of these efforts is to hasten the development of molecular diagnostics aligned with Seegene's vision of creating a ‘disease-free world.’

Complementing Global Initiatives

The Nature Awards MDx Impact Grants are designed to complement ongoing global initiatives in diagnostics, providing researchers with additional resources to accelerate practical solutions. The previous cycle in 2024-2025 notably supported projects focused on rapid detection of ViruResist Klebsiella pneumoniae and multiplex PCR testing for viral detection in immunocompromised patients, showcasing the program's significant impact in the field.

About Seegene

Founded over 20 years ago, Seegene Inc. has established itself as a leader in molecular diagnostics through its innovative research, development, manufacturing, and marketing of syndromic real-time PCR technologies. During the COVID-19 pandemic, Seegene made a substantial contribution by supplying over 340 million tests to more than 100 countries, exemplifying its strong global impact.

Seegene's patented quantitative syndromic PCR technology allows for the simultaneous detection of up to 14 pathogens causing similar symptoms in a single tube. With its extensive panel capabilities, the technology can extend coverage to dozens of clinically significant pathogens, providing quantitative information and infection co-status, which plays a vital role in complex infection management.

By leveraging its Technology Sharing Initiative, Seegene integrates its PCR technologies with its Seegene Digitalized Development System (SGDDS) to co-develop tailored diagnostic products with local institutions and leading experts worldwide. This collaborative approach not only fosters innovation but also propels the company in its mission to create a ‘disease-free world.’

About Nature Portfolio

Nature Portfolio is committed to serving the scientific community with high-quality products and services across biological, physical, chemical, and applied sciences. Established in 1869, Nature remains the leading weekly international science journal, with additional influential journals including Nature Communications and Scientific Reports. The content from Nature Portfolio reaches more than nine million unique visitors monthly, underscoring its significance in the realm of scientific communication.

For further details and to stay updated, visit Seegene.com and follow us on LinkedIn.

Get Involved

For researchers keen on addressing antibiotic resistance, we encourage you to apply before the November 20, 2025, deadline and contribute to advancing diagnostic solutions that can potentially transform healthcare landscapes worldwide.